Opko Health (OPK) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Opko Health (NASDAQ:OPK) announced its quarterly earnings results on Friday. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03, Briefing.com reports. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. The company had revenue of $250.00 million during the quarter, compared to analyst estimates of $264.04 million. During the same quarter last year, the firm posted ($0.08) earnings per share. The firm’s revenue was up 1.6% on a year-over-year basis.

Opko Health stock traded down $0.40 on Friday, hitting $3.09. 7,341,070 shares of the stock traded hands, compared to its average volume of 3,831,201. The company has a current ratio of 1.05, a quick ratio of 0.90 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $2.16 billion, a P/E ratio of -10.66 and a beta of 1.89. Opko Health has a 1 year low of $2.66 and a 1 year high of $6.40.

In other news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the stock in a transaction on Friday, August 17th. The stock was acquired at an average price of $5.54 per share, with a total value of $55,400.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $17,001,988.54. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have acquired 70,000 shares of company stock valued at $392,950 in the last three months. Insiders own 42.74% of the company’s stock.

A number of brokerages recently commented on OPK. ValuEngine raised Opko Health from a “sell” rating to a “hold” rating in a research note on Thursday, July 26th. BidaskClub raised Opko Health from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 24th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 price target on shares of Opko Health in a research note on Tuesday, August 7th. Finally, Barrington Research reaffirmed a “buy” rating and issued a $7.00 price target on shares of Opko Health in a research note on Friday, October 5th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $9.69.

ILLEGAL ACTIVITY NOTICE: This story was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/11/10/opko-health-opk-posts-quarterly-earnings-results-beats-estimates-by-0-03-eps.html.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

See Also: Diversification Important in Investing

Earnings History for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply